Cargando…

Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma

Alterations of sphingolipids and their metabolizing enzymes play a role in various diseases. However, peripheral biomarkers for such changes are limited. Particularly, in the increasingly reported involvement of neutral sphingomyelinase (NSM) with four described isoforms in tissues or cells, a perip...

Descripción completa

Detalles Bibliográficos
Autores principales: Mühle, Christiane, Kornhuber, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916453/
https://www.ncbi.nlm.nih.gov/pubmed/36768790
http://dx.doi.org/10.3390/ijms24032467
_version_ 1784886129758044160
author Mühle, Christiane
Kornhuber, Johannes
author_facet Mühle, Christiane
Kornhuber, Johannes
author_sort Mühle, Christiane
collection PubMed
description Alterations of sphingolipids and their metabolizing enzymes play a role in various diseases. However, peripheral biomarkers for such changes are limited. Particularly, in the increasingly reported involvement of neutral sphingomyelinase (NSM) with four described isoforms in tissues or cells, a peripheral marker is lacking. We here describe the detection of an NSM activity in human serum and plasma samples which hydrolyses fluorescently labeled sphingomyelin to ceramide in a time- and volume-dependent manner. Reaction rates were linear up to 10 days, and serum volumes above 2 vol-% were inhibitory. Biochemical properties were different from acid sphingomyelinase (ASM) with respect to detergent specificity (sodium deoxycholate), pH profile (pH 7–9), and cation dependence: Serum NSM activity was inhibited by EDTA ≥ 1 µM and restored in EDTA-anticoagulated plasma with the addition of ≥ 100 µM Co(2+). It was independent of Mg(2+), the typical cofactor of cellular NSM species, and even inhibited by [Mg(2+)] ≥ 20 mM. Serum NSM activity was not correlated with ASM activity and was independent of sex and age in 24 healthy adults. Since human peripheral NSM activity is very low and activities in rodents are even lower or undetectable, future research should aim to increase the reaction rate and determine the source of this enzymatic activity. The established activity could serve as a future biomarker or therapeutic target in diseases affected by sphingolipid derangements.
format Online
Article
Text
id pubmed-9916453
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99164532023-02-11 Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma Mühle, Christiane Kornhuber, Johannes Int J Mol Sci Article Alterations of sphingolipids and their metabolizing enzymes play a role in various diseases. However, peripheral biomarkers for such changes are limited. Particularly, in the increasingly reported involvement of neutral sphingomyelinase (NSM) with four described isoforms in tissues or cells, a peripheral marker is lacking. We here describe the detection of an NSM activity in human serum and plasma samples which hydrolyses fluorescently labeled sphingomyelin to ceramide in a time- and volume-dependent manner. Reaction rates were linear up to 10 days, and serum volumes above 2 vol-% were inhibitory. Biochemical properties were different from acid sphingomyelinase (ASM) with respect to detergent specificity (sodium deoxycholate), pH profile (pH 7–9), and cation dependence: Serum NSM activity was inhibited by EDTA ≥ 1 µM and restored in EDTA-anticoagulated plasma with the addition of ≥ 100 µM Co(2+). It was independent of Mg(2+), the typical cofactor of cellular NSM species, and even inhibited by [Mg(2+)] ≥ 20 mM. Serum NSM activity was not correlated with ASM activity and was independent of sex and age in 24 healthy adults. Since human peripheral NSM activity is very low and activities in rodents are even lower or undetectable, future research should aim to increase the reaction rate and determine the source of this enzymatic activity. The established activity could serve as a future biomarker or therapeutic target in diseases affected by sphingolipid derangements. MDPI 2023-01-27 /pmc/articles/PMC9916453/ /pubmed/36768790 http://dx.doi.org/10.3390/ijms24032467 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mühle, Christiane
Kornhuber, Johannes
Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma
title Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma
title_full Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma
title_fullStr Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma
title_full_unstemmed Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma
title_short Characterization of a Neutral Sphingomyelinase Activity in Human Serum and Plasma
title_sort characterization of a neutral sphingomyelinase activity in human serum and plasma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916453/
https://www.ncbi.nlm.nih.gov/pubmed/36768790
http://dx.doi.org/10.3390/ijms24032467
work_keys_str_mv AT muhlechristiane characterizationofaneutralsphingomyelinaseactivityinhumanserumandplasma
AT kornhuberjohannes characterizationofaneutralsphingomyelinaseactivityinhumanserumandplasma